Cargando…

The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chokr, Nora, Patel, Rima, Wattamwar, Kapil, Chokr, Samer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241340/ https://www.ncbi.nlm.nih.gov/pubmed/30519261 http://dx.doi.org/10.1155/2018/2458679

Ejemplares similares

Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab
por: Chokr, Nora, et al.
Publicado: (2018)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Auditory Brainstem Deficits from Early Treatment with a CSF1R Inhibitor Largely Recover with Microglial Repopulation
por: Milinkeviciute, Giedre, et al.
Publicado: (2021)

Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
por: Guo, Xinyu, et al.
Publicado: (2023)

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
por: Huemer, Florian, et al.
Publicado: (2021)

Immune Mechanisms in Myelodysplastic Syndrome
por: Glenthøj, Andreas, et al.
Publicado: (2016)

The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
por: Marco, Tucci, et al.
Publicado: (2019)

Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
por: Stern, Peter L., et al.
Publicado: (2021)

Institutional role conflict in the digital age: The case of diabetes management at school
por: Puckett, Cassidy, et al.
Publicado: (2023)

Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
por: Chanias, Ioannis, et al.
Publicado: (2021)

Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome
por: Tcvetkov, Nikolai, et al.
Publicado: (2020)

Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy
por: Nakatsuru, Kousei, et al.
Publicado: (2023)

Synapse Maturation and Developmental Impairment in the Medial Nucleus of the Trapezoid Body
por: Chokr, Sima M., et al.
Publicado: (2022)

Evaluation of the Marginal Fit of Computer-Aided Design (CAD) and Computer-Aided Manufacturing (CAM) Zirconia Bridges Fabricated With Different Firing Cycles of Veneering Porcelain: An In Vitro Study
por: Chokr, Hawraa, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
por: Maiorano, Brigida Anna, et al.
Publicado: (2021)

Signal transduction inhibitors in treatment of myelodysplastic syndromes
por: Bachegowda, Lohith, et al.
Publicado: (2013)

A systematic approach in the diagnosis of paediatric skull lesions: what radiologists need to know
por: Choudhary, Gagandeep, et al.
Publicado: (2019)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

The Rising Era of “Immunoporosis”: Role of Immune System in the Pathophysiology of Osteoporosis
por: Srivastava, Rupesh K, et al.
Publicado: (2022)

Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
por: Repáraz, David, et al.
Publicado: (2022)

Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
por: Yu, Yi-xuan, et al.
Publicado: (2023)

Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors
por: Clark, Curtis A., et al.
Publicado: (2022)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Assorted Methods for Decontamination of Aflatoxin M1 in Milk Using Microbial Adsorbents
por: Assaf, Jean Claude, et al.
Publicado: (2019)

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
por: Karaki, Soumaya, et al.
Publicado: (2016)

Gastric Cancer in the Era of Immune Checkpoint Blockade
por: Figueroa-Protti, Lucía, et al.
Publicado: (2019)

Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes
por: Yao, Kevin, et al.
Publicado: (2022)

Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis
por: Moiseev, Ivan, et al.
Publicado: (2022)

Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors
por: Aly, Ragia, et al.
Publicado: (2020)

The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria
por: Castello, Angelo, et al.
Publicado: (2022)

Circulating and Tumor-Associated Neutrophils in the Era of Immune Checkpoint Inhibitors: Dynamics, Phenotypes, Metabolism, and Functions
por: Gibellini, Lara, et al.
Publicado: (2023)

Immune dysregulation in myelodysplastic syndrome
por: Sugimori, Chiharu, et al.
Publicado: (2010)

The Abscopal Effect in the Era of Checkpoint Inhibitors
por: Kodet, Ondřej, et al.
Publicado: (2021)

Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan
por: Taketomi, Akinobu
Publicado: (2021)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
por: Zhang, Xiaoying, et al.
Publicado: (2023)

Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors
por: Duong, Sophie L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jsrjfiku39ftkikd1cpu8niprs